Government-Owned Inventions; Availability for Licensing, 45055 [E7-15622]

Download as PDF Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices whether the methodology and assumptions used to determine the estimates are logical; (e) ways to enhance the quality, utility, and clarity of the information being collected; and (f) ways to minimize the public burden through the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Send Comments and Requests for Further Information: Send your written comments, requests for more information on the proposed collection, or requests to obtain a copy of the data collection instrument(s) and instructions to: Mrs. Chris Rouleau, IHS Reports Clearance Officer, 801 Thompson Ave., Suite 450, Rockville, MD 20852–1601; call non-toll free (301) 443–5938; send via facsimile to (301) 443–2316; or send your e-mail requests, comments, and return address to: Christina.Rouleau@ihs.gov. Comment Due Date: Your comments regarding this information collection are best assured of having full effect if received within 60 days of the date of this publication. Dated: August 3, 2007. Charles W. Grim, Assistant Surgeon General, Director, Indian Health Service. [FR Doc. 07–3895 Filed 8–9–07; 8:45 am] BILLING CODE 4165–16–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. sroberts on PROD1PC70 with PROPOSALS AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ VerDate Aug<31>2005 16:37 Aug 09, 2007 Jkt 211001 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Treatment for Cystic Fibrosis Cells and Other Reduced ClØConductance Cells Description of Technology: Cystic fibrosis is the most common fatal genetic disease among Caucasians. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) protein. A normal CFTR transports chloride ions across the membrane of epithelial cells lining several organs in the body such as the lungs and the pancreas. The most debilitating consequence of the defective CFTR protein occurs in the lungs of cystic fibrosis patients, where insufficient chloride transport prevents water from exiting epithelial cells. This causes the lungs to produce abnormally thick, sticky mucus that clogs the airways and leads to fatal lung infections. Currently there is no cure for the disease. Present treatments result in undesired side effects such as cardiac, renal, and/or central nervous system tissue. The NIH has developed a method of identifying cystic fibrosis transmembrane regulator binding compounds for treating cells having a reduced Cl¥conductance, such as cystic fibrosis cells. It has also identified a compound, 1,3-Diallyl-8cyclohexylxanthine (DAX), for potential treatment of cystic fibrosis. Because DAX has specificity in target areas of activity, treatment with this compound can potentially prevent all of the complications of cystic fibrosis including the production of abnormal mucus and without undesired side effects. DAX is active in extremely low concentrations. Applications: Diagnostic; Therapeutic agent for the treatment of cells having a reduced Cl¥conductance. Market: This is intended for cystic fibrosis or other reduced Cl¥conductance cells; Approximately 70,000 children and young adults worldwide, including 30,000 in the U.S. and 30,000 in Europe. Development Status: Dr. Pollard has performed pre-clinical testing. Inventors: Dr. Harvey B. Pollard and Dr. Kenneth A. Jacobson (NIDDK). Publications: 1. N Arispe et al. ‘‘Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8– cyclopentyl–1,3–dipropylxanthine (CPX) and 1,3–diallyl–8– cyclohexylxanthine (DAX),’’ J Biol Chem. 1998 Mar 6;273(10):5727–5734. 2. KA Jacobson, C Guay-Broder, PJM van Galen, C Gallo-Rodriguez, N PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 45055 Melman, O Eidelman, HB Pollard. ‘‘Stimulation by alkylxanthines of chloride efflux in CFPAC-cells does not involve A1-adenosine receptors,’’ Biochemistry, 1995 Jul 18;34(28):9088– 9094. Patent Status: U.S. Patent No. 5,877,179 issued 02 Mar 1999 (HHS Reference No. E–138– 1992/1–US–01). This patent is for identifying binding compounds and composition of matter. U.S. Patent No. 6,083,954 issued 04 Jul 2000 (HHS Reference No. E–138– 1992/1–US–02). This patent is for treating CF. Foreign patent rights available. Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Catherine A. Wendelken; 301/435–5282; wendelkenc@od.nih.gov. Dated: August 3, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–15622 Filed 8–9–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Research Program Project on Hypertension in Youth. Date: September 7, 2007. Time: 8 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: Double Tree Washington, 1515 Rhode Island Ave., NW., Washington, DC 20005. Contact Person: Holly Patton, PhD, Scientific Review Administrator, Review E:\FR\FM\10AUN1.SGM 10AUN1

Agencies

[Federal Register Volume 72, Number 154 (Friday, August 10, 2007)]
[Notices]
[Page 45055]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15622]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Treatment for Cystic Fibrosis Cells and Other Reduced Cl-Conductance 
Cells

    Description of Technology: Cystic fibrosis is the most common fatal 
genetic disease among Caucasians. It is caused by a defect in the 
cystic fibrosis transmembrane regulator (CFTR) protein. A normal CFTR 
transports chloride ions across the membrane of epithelial cells lining 
several organs in the body such as the lungs and the pancreas. The most 
debilitating consequence of the defective CFTR protein occurs in the 
lungs of cystic fibrosis patients, where insufficient chloride 
transport prevents water from exiting epithelial cells. This causes the 
lungs to produce abnormally thick, sticky mucus that clogs the airways 
and leads to fatal lung infections. Currently there is no cure for the 
disease. Present treatments result in undesired side effects such as 
cardiac, renal, and/or central nervous system tissue.
    The NIH has developed a method of identifying cystic fibrosis 
transmembrane regulator binding compounds for treating cells having a 
reduced Cl-conductance, such as cystic fibrosis cells. It has also 
identified a compound, 1,3-Diallyl-8-cyclohexylxanthine (DAX), for 
potential treatment of cystic fibrosis. Because DAX has specificity in 
target areas of activity, treatment with this compound can potentially 
prevent all of the complications of cystic fibrosis including the 
production of abnormal mucus and without undesired side effects. DAX is 
active in extremely low concentrations.
    Applications: Diagnostic; Therapeutic agent for the treatment of 
cells having a reduced Cl-conductance.
    Market: This is intended for cystic fibrosis or other reduced Cl-
conductance cells; Approximately 70,000 children and young adults 
worldwide, including 30,000 in the U.S. and 30,000 in Europe.
    Development Status: Dr. Pollard has performed pre-clinical testing.
    Inventors: Dr. Harvey B. Pollard and Dr. Kenneth A. Jacobson 
(NIDDK).
    Publications:
    1. N Arispe et al. ``Direct activation of cystic fibrosis 
transmembrane conductance regulator channels by 8-cyclopentyl-1,3-
dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX),'' J 
Biol Chem. 1998 Mar 6;273(10):5727-5734.
    2. KA Jacobson, C Guay-Broder, PJM van Galen, C Gallo-Rodriguez, N 
Melman, O Eidelman, HB Pollard. ``Stimulation by alkylxanthines of 
chloride efflux in CFPAC-cells does not involve A1-adenosine 
receptors,'' Biochemistry, 1995 Jul 18;34(28):9088-9094.
    Patent Status:
    U.S. Patent No. 5,877,179 issued 02 Mar 1999 (HHS Reference No. E-
138-1992/1-US-01). This patent is for identifying binding compounds and 
composition of matter.
    U.S. Patent No. 6,083,954 issued 04 Jul 2000 (HHS Reference No. E-
138-1992/1-US-02). This patent is for treating CF.
    Foreign patent rights available.
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Catherine A. Wendelken; 301/435-5282; 
wendelkenc@od.nih.gov.

    Dated: August 3, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-15622 Filed 8-9-07; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.